Generation Bio EBITDA Margin 2020-2023 | GBIO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Generation Bio (GBIO) over the last 10 years. The current EBITDA margin for Generation Bio as of December 31, 2023 is .
| Generation Bio EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.207B | $0.006B |
| Generation Bio Co. is a genetic medicines company. It is focused on creating gene therapy for patients suffering from both rare and prevalent diseases. Generation Bio Co. is based in CAMBRIDGE, Mass. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $15.785B | 5.70 |
| Dr Reddy's Laboratories (RDY) | India | $12.479B | 19.73 |
| BridgeBio Pharma (BBIO) | United States | $5.191B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $5.181B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.956B | 2.26 |
| Amphastar Pharmaceuticals (AMPH) | United States | $2.052B | 14.27 |
| Supernus Pharmaceuticals (SUPN) | United States | $1.664B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $0.483B | 0.00 |
| Personalis (PSNL) | United States | $0.081B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.070B | 0.00 |
| Acasti Pharma (ACST) | Canada | $0.028B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.024B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.004B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |